Document is current
Any future updates will be listed below
-
Authors
Mysore, Venkatesh P.
Zhou, Zhi-Wei
Ambrogio, Chiara https://orcid.org/0000-0003-4122-701X
Li, Lianbo https://orcid.org/0000-0003-0107-7125
Kapp, Jonas N. https://orcid.org/0000-0002-7308-559X
Lu, Chunya
Wang, Qi
Tucker, Maxwell R. https://orcid.org/0000-0002-1606-8806
Okoro, Jeffrey J.
Nagy-Davidescu, Gabriela
Bai, Xiaochen https://orcid.org/0000-0002-4234-5686
Plückthun, Andreas https://orcid.org/0000-0003-4191-5306
Jänne, Pasi A. https://orcid.org/0000-0002-7821-4928
Westover, Kenneth D. https://orcid.org/0000-0003-3653-5923
Shan, Yibing https://orcid.org/0000-0002-3865-8110
Shaw, David E. https://orcid.org/0000-0001-8265-5761
- License Information
-
More Information
Article History
Received: 14 August 2020
Accepted: 25 August 2021
First Online: 8 October 2021
Competing interests
: P.A.J. reports grants from AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli-Lilly, Takeda Oncology, Astellas, PUMA and Revolution Medicines and personal fees from AstraZeneca, Boehringer Ingelheim, Pfizer, Roche/Genentech, Eli-Lilly, Chugai, Ignyta, Loxo Oncology, SFJ Pharmaceuticals, Voronoi, Daiichi Sankyo, Biocartis, Novartis, Sanofi Oncology, Takeda Oncology, Mirati Therapeutics, Trasncenta, Silicon Therapeutics, Syndax, Bayer, Esai, Allorion Therapeutics, Accutar Biotech and AbbVie outside the submitted work; P.A.J. also receives postmarketing royalties from a DFCI-owned patent on EGFR mutations issued and licensed to Lab Corp. K.D.W. receives or has received grant funding from Revolution Medicines and Astellas outside the submitted work. He also is on the scientific advisory board for Vibliome Therapeutics. The remaining authors declare no competing interests.
